Alkermes Advances Alixorexton to Phase 3 for Narcolepsy Treatment
Alkermes is advancing a Phase 3 clinical program for narcolepsy, aiming to expand its sleep-wake disorder portfolio. By targeting the underlying neurological deficits of the condition, the company seeks to ... Read More